Nuestro blog

The challenges associated with conducting central nervous system clinical research all impact sponsors’ and study teams’ ability to gather stronger therapeutic evidence—but they also prime CNS studies for decentralization.

Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.

Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.

Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.

One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.

The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.

eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.

Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.

Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.